Valneva Gestione

Gestione criteri di controllo 1/4

Valneva Il CEO è Thomas Lingelbach, nominato in May2013, e ha un mandato di 11.5 anni. la retribuzione annua totale è € 919.56K, composta da 58.8% di stipendio e 41.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.24% delle azioni della società, per un valore di € 729.45K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.9 anni e 1.7 anni.

Informazioni chiave

Thomas Lingelbach

Amministratore delegato

€919.6k

Compenso totale

Percentuale dello stipendio del CEO	58.8%
Mandato del CEO	11.5yrs
Proprietà del CEO	0.2%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	1.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Thomas Lingelbach rispetto agli utili di Valneva?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-€7m
Jun 30 2024	n/a	n/a	-€32m
Mar 31 2024	n/a	n/a	-€24m
Dec 31 2023	€920k	€541k	-€101m
Sep 30 2023	n/a	n/a	-€113m
Jun 30 2023	n/a	n/a	-€7m
Mar 31 2023	n/a	n/a	-€135m
Dec 31 2022	€784k	€525k	-€143m
Sep 30 2022	n/a	n/a	€73m
Jun 30 2022	n/a	n/a	-€159m
Mar 31 2022	n/a	n/a	-€72m
Dec 31 2021	€769k	€420k	-€73m
Sep 30 2021	n/a	n/a	-€248m
Jun 30 2021	n/a	n/a	-€125m
Mar 31 2021	n/a	n/a	-€91m
Dec 31 2020	€649k	€376k	-€64m
Sep 30 2020	n/a	n/a	-€62m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€8m
Dec 31 2019	€1m	€384k	-€2m
Sep 30 2019	n/a	n/a	€4m
Jun 30 2019	n/a	n/a	€1m
Mar 31 2019	n/a	n/a	€7m
Dec 31 2018	€694k	€377k	€3m
Sep 30 2018	n/a	n/a	-€7m
Jun 30 2018	n/a	n/a	-€7m
Mar 31 2018	n/a	n/a	-€8m
Dec 31 2017	€649k	€367k	-€11m

Compensazione vs Mercato: La retribuzione totale di Thomas ($USD 963.90K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 1.03M ).

Compensazione vs guadagni: La retribuzione di Thomas è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Thomas Lingelbach (61 yo)

11.5yrs

Mandato

€919,563

Compensazione

Mr. Thomas Lingelbach has been the Chief Executive Officer of Valneva SE since May 2013 and served as its Chairman and Member of the Management Board since May 10, 2013 until December 20, 2023 and serves a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Lingelbach	President	11.5yrs	€919.56k	0.24% € 729.5k
Peter Buhler	Chief Financial Officer	no data	€558.83k	0.028% € 84.7k
Franck Grimaud	Chief Business Officer	less than a year	€401.34k	0.39% € 1.2m
Juan-Carlos Jaramillo	Chief Medical Officer	less than a year	€539.76k	0.028% € 84.7k
Dipal Patel	Chief Commercial Officer	less than a year	€516.75k	Nessun dato
Vincent Dequenne	Chief Operating Officer	no data	Nessun dato	Nessun dato
Hanneke Schuitemaker	Chief Scientific Officer	less than a year	Nessun dato	Nessun dato
Joshua Drumm	Vice President of Investor Relations	3.3yrs	Nessun dato	Nessun dato
Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations	no data	Nessun dato	Nessun dato
Petra Pesendorfer	Chief People Officer	less than a year	Nessun dato	Nessun dato
Christian Taucher	Head of Global Medical Affairs	no data	Nessun dato	Nessun dato
Susanne Eder-Lingelbach	Head of Clinical Operations	no data	Nessun dato	Nessun dato

0.9yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di AYJ non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Lingelbach	President	less than a year	€919.56k	0.24% € 729.5k
James Sulat	Director	less than a year	€74.07k	0.019% € 57.4k
Alexander Von Gabain	Member of Scientific Advisory Board	4.8yrs	€10.00k	Nessun dato
James Connolly	Director	less than a year	€66.11k	Nessun dato
Kathrin Jansen	Director	less than a year	€28.25k	Nessun dato
Mailys Ferrere	Director	less than a year	Nessun dato	Nessun dato
George R. Siber	Member of Scientific Advisory Board	5yrs	Nessun dato	Nessun dato
Ralf Leo Clemens	Chair of Scientific Advisory Board	5.3yrs	€2.92k	Nessun dato
Norman Baylor	Member of Scientific Advisory Board	5yrs	Nessun dato	Nessun dato
Anne-Marie Graffin	Chairman	less than a year	€74.30k	0.0088% € 27.0k
Thomas Decker	Member of Scientific Advisory Board	2.5yrs	Nessun dato	Nessun dato
Michael Pfleiderer	Member of Scientific Advisory Board	2.5yrs	Nessun dato	Nessun dato

1.7yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di AYJ non è considerato esperto (durata media del mandato 1.7 anni), il che suggerisce un nuovo consiglio.

Valneva Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Announces Board Changes

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Recent updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Forecast to breakeven in 2024

Third quarter 2024 earnings released: €0.066 loss per share (vs €0.25 loss in 3Q 2023)

New minor risk - Financial position

Valneva SE to Report Nine Months, 2025 Results on Nov 13, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

New minor risk - Shareholder dilution

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Second quarter 2024 earnings released: €0.19 loss per share (vs €0.12 loss in 2Q 2023)

No longer forecast to breakeven

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

First quarter 2024 earnings released: EPS: €0.42 (vs €0.13 loss in 1Q 2023)

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Full year 2023 earnings released: €0.73 loss per share (vs €1.24 loss in FY 2022)

New minor risk - Profitability

Now 20% undervalued after recent price drop

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Forecast to breakeven in 2024

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

No longer forecast to breakeven

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Third quarter 2023 earnings released: €0.25 loss per share (vs €0.68 profit in 3Q 2022)

New minor risk - Share price stability

Valneva Se Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: €0.12 loss per share (vs €1.34 loss in 2Q 2022)

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

New minor risk - Financial position

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Forecast breakeven date moved forward to 2023

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

First quarter 2023 earnings released: €0.13 loss per share (vs €0.24 loss in 1Q 2022)

No longer forecast to breakeven

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Investor sentiment improved over the past week

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

No longer forecast to breakeven

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Second quarter 2022 earnings released: €1.34 loss per share (vs €0.60 loss in 2Q 2021)

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Forecast breakeven date pushed back to 2024

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO